Thymosin Beta-4
- Category
- Tissue Repair & Recovery
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A 43-amino-acid peptide, sold mostly as the synthetic fragment TB-500 and marketed for wound healing and tendon and muscle repair. The case rests almost entirely on animal and mechanism work, so the human benefit case is weak. It promotes blood-vessel growth and cell migration, leaving a theoretical tumor concern unresolved and long-term safety unestablished. Not an approved US drug; most supply consists of unregulated products sold online, of uncertain purity.
Read Full recordStudied uses & evidence
Studied uses(6)
Accelerated wound healing with increased reepithelialization (42-61% improvement)
LowThe 42-61% figure comes from a 1999 rat wound model; human skin trials missed their goals.
Reduced scar formation and fibrosis through decreased myofibroblast activity
LowConsistent animal and lab data show fewer scar-forming cells; no human anti-fibrosis trials yet.
Promoted corneal wound healing and reduced inflammation in eye injury models
MediumExtensive animal data plus human eye trials, though pivotal trials showed only trends or missed goals.
Evidence limits
- Evidence Level
- Moderate Evidence (Strong Preclinical, Limited Human)
Thymosin Beta-4 has exceptionally strong preclinical evidence across dermal, corneal, cardiac, and neurological injury models. Human clinical trials are more limited. RGN-259 reached Phase 3 trials in neurotrophic keratopathy and dry eye; encouraging secondary and subgroup findings have not established efficacy, and the dry-eye trials missed their prespecified coprimary endpoints. Topical Tb4 has been tested in small human wound healing studies showing accelerated healing. Cardiac applications remain in preclinical stages. The full 43-amino-acid protein has a substantially larger evidence base than the TB-500 fragment.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
HighPromotes cell migration, angiogenesis, and tissue remodeling — same concerns as TB-500 (its active fragment).
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Long-term human safety not established
ModeratePromotes angiogenesis/cell migration; theoretical tumor concern
ModerateMild injection site reactions when given subcutaneously
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.